Scribe Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Scribe Therapeutics Inc.: Is Infosys Ltd. worth buying?
Item: Scribe Therapeutics Inc.
Rating: 0.32800
Author: Trendlyne DVM scores

about

Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic ...

19.12 -1.55 (-7.50%)

51.72% Fall from 52W High

298.5K

XNAS Volume

XNAS 13 Oct, 2026 5:30 PM (EDT)

Not Eligible

Expensive Valuation

0.0 / 100

Technically Bearish

13.1 / 100

No estimates available

Scribe Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Scribe Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic ...

51.72% Fall from 52W High

SWOT Analysis

Scribe Therapeutics Inc Live Price Chart

Scribe Therapeutics Inc Live Price Chart